Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 1 Descriptive results (main aspects)

From: Regional differences in health care of patients with inflammatory bowel disease in Germany

  

Crohn Disease (CD)

Ulcerative Colitis (UC)

Total

  

n = 9282

n = 12,489

n = 21,771

Regular specialist visits

 

20 %

22 %

21 %

Medication

Permanent steroid therapy

Received medication

28 %

17 %

22 %

With continuous specialist supporta

32 %

37 %

34 %

Permanent immunosuppressive therapy

Received medication

22 %

11 %

16 %

With continuous specialist supporta

34 %

38 %

36 %

TNF-α inhibitors therapy

Received medication

7 %

2 %

4 %

With continuous specialist supporta

50 %

51 %

50 %

Surveillance colonoscopy (UC patients aged ≥ 50 years (n = 6664))

/

9 %

/

IBD-related hospitalization

13 %

5 %

9 %

  1. aOnly patients who received the relevant medication were considered